Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
Appointed director
|
|
Cascadian Therapeutics, Inc. (CASC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/18/2013 |
8-K/A
| Appointed a new director |
| 11/19/2010 |
8-K/A
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits |
| 12/07/2009 |
8-K/A
| Appointed a new director |
| 02/21/2008 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"Consent of Beach, Fleischman & Co., P.C., independent accounting firm, with respect to ProlX Pharmaceuticals Corporation",
"Consent of Deloitte & Touche LLP, independent registered chartered accountants, with respect to Biomira Inc",
"Consent of McConnell & Jones LLP, independent accounting firm with respect to ProlX Pharmaceuticals Corporation",
"Biomira Inc.'s historical audited consolidated financial statements as of December 31, 2006 and 2005, and for each of the years in the three-year period ended December 31, 2006",
"Biomira Inc.'s unaudited consolidated financial statements for the interim period ended September 30, 2007 and September 30, 2006",
"ProlX Pharmaceuticals Corporation historical audited financial statements as of December 31, 2005 and 2004 and the unaudited financial statements for the nine months ended September 30, 2006 and 2005" |
|
|
|